Albert Garcia-Romeu
Associate Professor at Johns Hopkins University School of Medicine
Data updated
Research Footprint
Albert Garcia-Romeu appears in 32 tracked papers (2014–2026), most studied alongside Psilocybin, LSD and Ketamine, across Substance Use Disorders (SUD), Depressive Disorders and Anxiety Disorders.
Most-cited paper: Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction (899 citations).
Frequent co-authors: Matthew Johnson, Roland Griffiths and Sandeep Nayak.
Publication Landscape
How the 32 papers Blossom tracks for Albert Garcia-Romeu line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Albert Garcia-Romeu's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 32 of 32 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Albert Garcia-Romeu publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Albert Garcia-Romeu publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Dr. Albert Garcia-Romeu is a psychologist at the Johns Hopkins Center for Psychedelic and Consciousness Research. His research focuses on the clinical applications of psilocybin, particularly for smoking cessation and alcohol use disorder. He also explores the relationship between self-transcendence, spiritual experiences, and long-term improvements in mental health and well-being.
Key Impact
Leading researcher on the use of psilocybin for addiction and the role of spirituality in mental health.
Collaboration Network
22 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Albert Garcia-Romeu's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Albert Garcia-Romeu is associated with.
Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
The Johns Hopkins Center for Psychedelic and Consciousness Research sits within the School of Medicine in Baltimore and is one of the most established programmes of its kind. It opened in 2019 with roughly 17 million dollars in private donations, and was founded under Roland Griffiths, whose earlier psilocybin work helped revive modern clinical study of these compounds. Frederick Barrett took over as director in 2023. The centre studies how classic psychedelics such as psilocybin affect brain function, cognition and mood, and runs trials in conditions including depression, tobacco dependence and anorexia. Its scientists combine clinical trials with neuroimaging and questionnaire measures of the psychedelic experience, and much of the field's shared vocabulary traces back to work done here.
View stakeholder →